Masashi Matsui
New York Medical College
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Masashi Matsui.
European Journal of Pharmacology | 2000
Yoshiaki Fukuda; Hiroshi Kawashima; Kayo Saito; Norio Inomata; Masashi Matsui; Toshihiro Nakanishi
The effect of human recombinant plasma-type platelet-activating factor (PAF) acetylhydrolase was examined in two murine models, PAF-induced death and active anaphylactic models. In the PAF-induced death model where mice were injected intravenously with 40 microg/kg of PAF, the administration of PAF acetylhydrolase reduced mortality in a dose-dependent manner, showing complete prevention of mortality at 1.0 mg/kg. Myeloperoxidase activity, the marker for neutrophils, was increased in the lung by PAF injection, and the PAF acetylhydrolase treatment significantly reversed the increase in myeloperoxidase activity. As in the PAF-induced model, PAF acetylhydrolase also decreased mortality in the active anaphylactic shock model where bovine serum albumin was injected intravenously to mice previously immunized with bovine serum albumin. The protective effect of PAF acetylhydrolase on mortality in this model was significant at 1.0 mg/kg. These results suggest that PAF is an important mediator in the lethality of systemic anaphylaxis, and that PAF acetylhydrolase may be beneficial for treatment of anaphylactic shock.
Cancer Immunology, Immunotherapy | 1988
Yoshiaki Fukuda; Kohzoh Imai; Kenju Miura; Masashi Matsui; Toshihiro Nakanishi; Hiroshi Nakazato; Johji Masukawa; Toshiyuki Higashide; Yuji Hinoda; Teruhisa Noguchi; Akira Yachi
SummaryThere have been few reports stating that monoclonal antibody alone inhibits human solid tumor growth in vivo. The present study demonstrated that monoclonal antibody S1 (IgG2a), which recognized the antigenic determinant of the carbohydrate moiety, showed antibody-dependent cell (or macrophage)-mediated cytotoxicity (ADCC or ADMC) in conjunction with murine splenocytes of both BALB/c and athymic mice. In vivo experiments demonstrated that the antibody S1 clearly prolonged the survival of athymic mice which had been inoculated with a human liver carcinoma cell line. In addition, the antibody S1 significantly suppressed the human hepatoma line transplanted s.c. into nude mice. 125I-Labeled monoclonal antibody S1 revealed that the antibody accumulated significantly in the tumor mass. Many mononuclear cells were observed surrounding tumor cells when the antibody was given. This model system might be useful for analyzing the ADCC (or ADMC) mechanism in vivo.
Journal of Immunology | 1987
Masashi Matsui; Massimo Temponi; Soldano Ferrone
Cancer Research | 1985
P. G. Natali; Aldo Bigotti; Renato Cavaliere; Shuen-Kuei Liao; Masaru Taniguchi; Masashi Matsui; Soldano Ferrone
Journal of Biochemistry | 1994
Nobuhiro Ishida; Masafumi Tsujimoto; Toshimichi Kanaya; Akio Shimamura; Nobuo Tsuruoka; Shiho Kodama; Toyoko Katayama; Shinzo Oikawa; Masashi Matsui; Toshihiro Nakanishi; Jun Kobayashi; Hiroshi Nakazato
Japanese Journal of Cancer Research | 1985
Masashi Matsui; Toshihiro Nakanishi; Teruhisa Noguchi; Kohzoh Imai; Akira Yachi; Soldano Ferrone
Biochemical and Biophysical Research Communications | 2001
Asako Nagahira; Kazuhiro Nagahira; Hidenobu Murafuji; Keiichi Abe; Koji Magota; Masashi Matsui; Shinzo Oikawa
Journal of Immunology | 1988
Masashi Matsui; Toshihiro Nakanishi; Teruhisa Noguchi; Soldano Ferrone
Archive | 1986
Toshihiro Nakanishi; Masashi Matsui; Kenju Miura; Yoshiaki Fukuda; Teruhisa Noguchi
Archive | 1996
Kengo Akimoto; Masashi Matsui; Satomichi Yoshimura